Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
Tiffany Barnes, Tyler Brady, Nicolette Schuko, Amy Nguyen, Jagadish Beloor, Johnathan D. Guest, Anastasia A. Aksyuk, Kevin M. Tuffy, Tianhui Zhang, Katie Streicher, Elizabeth J. Kelly, Gustavo H. Kijak
Abstract
mutagenesis and molecular modeling. A combination of mutations at two spike protein positions, namely, 446 and 493, was sufficient to enhance BA.1 susceptibility to AZD7442 to levels similar to the Wuhan-Hu-1+D614G ancestral virus. The evolving nature of the SARS-CoV-2 pandemic warrants continuing real-time global molecular surveillance and mechanistic studies of therapeutic MAbs for COVID-19.
Topics & Concepts
NeutralizationVirologyMonoclonal antibodyIn vitroEpitopeCoronavirusMutagenesisVirusBiologyAntibodyMutationChemistryCoronavirus disease 2019 (COVID-19)GeneGeneticsMedicineInfectious disease (medical specialty)DiseasePathologySARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchAnimal Virus Infections Studies